What’s Happening

Project to investigate the use of ITIH3 biomarker in screening of individuals with gastric cancer risk

Singapore biomedical firm Restalyst has developed a COVID-19 antibody test, COVID19N-REAAD™, which will be instrumental in establishing disease prevalence in populations and the exposure risk factors associated with infection. Press release was made to countries…

This is a product intended for qualitative detection of IgG antibodies to SARS-CoV-2 Nucleocapsid Protein in human serum and plasma.

This a lateral flow chromatography immunoassay intended for the qualitative detection and differentiation of IgM and IgG antibodies against SARS-CoV-2 in human plasma, serum, finger pricked whole blood or whole blood.

18-21 Nov 2019. Restalyst participated in Medica 2019 under the Singapore Pavilion to promote her innovative cancer tests to the world.

12 – 15 Nov 2018 As part of its commitment to continuous innovation, Restalyst will be participating in Medica 2018. Visit us at Singapore Pavilion Hall 3 Booth G74.

GC-REAAD™, an in-vitro diagnostic medical device for the early detection of gastric cancer, was developed based on competitive ELISA platform in 2015. It was recently improved to a sandwich ELISA platform and approved by Singapore…

Singapore’s Restalyst develops new method to improve liver cancer diagnosis

The Chief Executive of the Hong Kong SAR, Mr C Y Leung, welcomed new foreign and Mainland investors at the Government House.

As part of the group re-branding exercise, ResteLab issued a complimentary Launch Pack Special for General Practitioners.

Doctors were invited to a lunch seminar on the use of the Prostate Health Index (phi) test as an effective non-invasive test for prostate cancer.

This ELISA-based diagnostic kit (known as HCC REAAD) was developed by Restalyst based on patented technology by the Chang Gung Memorial Hospital (Taiwan).

This ELISA-based diagnostic kit (known as GC-REAAD) was developed by Restalyst together with the National University of Singapore.